Manufacturing Part Of GSK Proposal For Single Dose Antimalarial In India
Executive Summary
GlaxoSmithKline has proposed to market and manufacture antimalarial Krintafel in India and an expert panel has sought additional information to progress a review of these plans. GSK and partner MMV aim to ensure that the cost of the therapy does not impede access.
You may also be interested in...
Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit
The latest drug development news and highlights from our US FDA Performance Tracker.
GSK’s Malaria Drug Tafenoquine Heads To US FDA Panel Review With Agency Backing
Approval could bring GlaxoSmithKline a tropical disease priority review voucher.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.